

This PANNA newsletter will also be available at the website: [www.pannastudy.com](http://www.pannastudy.com)

A newsletter will be issued once per 4 months to update you on the status of the study and inclusions.

### Centres

All centres in *The Netherlands; UK; Italy; Germany; Belgium; Ireland* are open for inclusion.

*Canada*: ethics approval.

*Spain*: an additional centre (Granada) will participate.

*France*: working on submission.



### List of compounds under investigation

#### panna

Etravirine, Intence, ETV  
Emtricitabine, Emtriva or FTC  
Tenofovir, Viread, TDF  
Atazanavir, Reyataz, ATV  
Fosamprenavir, Telzir, FPV  
Darunavir, Prezista, DRV  
Tipranavir, Aptivus, TPV  
Indinavir, Crixivan, IDV  
Raltegravir, Isentress, RAL  
Enfuvirtide, Fuzeon, T-20  
Maraviroc, Celsentri, MVC  
Efavirenz, Stocrin, EFV\*  
\*UK/Ireland only

### Inclusions

38 subjects signed informed consent.



### Emtricitabine / tenofovir arms closed now!


Patients on tenofovir / emtricitabine as the only compounds of the PANNA list cannot be included anymore.

### First results presented

#### 12th International Workshop on Clinical Pharmacology of HIV Therapy

We presented the first raltegravir data collected in the PANNA study in Miami. See results below.

#### Individual AUCt values



#### Cord blood/maternal plasma ratios

	conc maternal at delivery (mg/L)	conc. cord blood (mg/L)	cord blood / maternal plasma ratio
GB0201	0.615	0.628	1.02
IT0103	0.063	0.073	1.16

### Conclusion

In this small population (n=6) exposure to raltegravir was not lower during pregnancy (third trimester) than post-partum. This is in contrast to a number of other antiretroviral agents, especially protease inhibitors.

Raltegravir efficiently crosses the placenta.

These results need to be confirmed in a larger group of patients.

Thanks to the investigator contributing to these data (see the poster enclosed).

### Have a nice holiday season!

**I will be on holiday from June 17 – July 18.** In my absence you can contact David Burger in case of questions. E-mail [d.burger@akf.umcn.nl](mailto:d.burger@akf.umcn.nl). Telephone number as below.

Angela Colbers

Project manager

E-mail: [A.Colbers@akf.umcn.nl](mailto:A.Colbers@akf.umcn.nl)

[HIVPharmacology@akf.umcn.nl](mailto:HIVPharmacology@akf.umcn.nl)

Radboud University Nijmegen Medical Centre, Internal postal code 864,

Department of Pharmacy,

P.O. Box 9101, 6500 HB Nijmegen

Phone: + 31 (0)24 - 361 64 05

Fax: + 31 (0)24- 366 87 55